Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.

Status Completed

Clinical Trial Summary

These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.

Clinical Trial Description

The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to present challenges despite widespread vaccination efforts, with breakthrough infections remaining a concern. This has led to increased interest in exploring alternative preventive measures, including dietary and natural product-based interventions. Previous studies have demonstrated the potential of herbal medicines in inhibiting viral infections and as therapies for COVID-19. Additionally, research has identified various herbal medicines with inhibitory properties against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, highlighting their potential in combating the virus. Here Researchers found that novel herbal medicine formula Kang Guan Recipe (KGR) is a potent inhibitor against SARS-CoV-2 viral infection. Researchers demonstrated that KGR showed inhibitory activity against variants of concern (VOCs) of SARS-CoV-2 infection. Moreover, they also found that KGR can block the interaction of viral Spike and human angiotensin-converting enzyme 2 (ACE2). Furthermore, Researchers assessed the inhibitory effect of KGR on SARS-CoV-2 viral entry in vivo and observed that serum samples from healthy human subjects exhibited suppressive activity against various SARS-CoV-2 variants after consuming KGR. These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06291883
Study type	Interventional
Source	China Medical University Hospital
Contact
Status	Completed
Phase	Phase 1
Start date	February 9, 2023
Completion date	February 8, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05091411` - Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)	Phase 3
Completed	`NCT05107375` - Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine	Phase 3
Active, not recruiting	`NCT05128643` - Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)	Phase 3
Completed	`NCT04988217` - Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)	Phase 1/Phase 2
Completed	`NCT04579393` - Fostamatinib for Hospitalized Adults With COVID-19	Phase 2
Withdrawn	`NCT04390217` - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia	Phase 2
Recruiting	`NCT05047783` - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19	Phase 2
Completed	`NCT04646044` - A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19	Phase 1
Recruiting	`NCT05092568` - Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Completed	`NCT05364268` - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed	`NCT06189040` - Immunogenicity After COVID-19 Vaccines in Adapted Schedules	Phase 4
Recruiting	`NCT04401436` - COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Not yet recruiting	`NCT04395742` - 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Recruiting	`NCT04388631` - Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
Completed	`NCT05501288` - Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019	N/A
Active, not recruiting	`NCT05216471` - Identify Coronavirus Disease by Chest X-ray
Terminated	`NCT04672564` - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients	Phase 3
Completed	`NCT04967781` - Autoimmunity Contributes to the Severe Progression of COVID-19
Completed	`NCT04678830` - Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19	Phase 2
Completed	`NCT04497194` - Registry of COVID-19 Patients at AOUI Verona